ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Multiomics Data Analysis and Identification of Immune-Related Prognostic Signatures With Potential Implications in Prognosis and Immune Checkpoint Blockade Therapy of Glioblastoma

Ma, Shuai; Wang, Fang; Wang, Nan; Jin, Jiaqi; Ba, Yixu; Ji, Hang; Du, Jianyang*; Hu, Shaoshan*哈尔滨医科大学; 郑州大学
Frontiers in Neurology2022-5-20DOI: 10.3389/fneur.2022.886913
2被引7阅读
引用收藏
分享

摘要

BackgroundIn recent years, glioblastoma multiforme (GBM) has been a concern of many researchers, as it is one of the main drivers of cancer-related deaths worldwide. GBM in general usually does not responding well to immunotherapy due to its unique microenvironment. MethodsTo uncover any further informative immune-related prognostic signatures, we explored the immune-related distinction in the genetic or epigenetic features of the three types (expression profile, somatic mutation, and DNA methylation). Twenty eight immune-related hub genes were identified by Weighted Gene Co-Expression Network Analysis (WGCNA). The findings showed that three genes (IL1R1, TNFSF12, and VDR) were identified to construct an immune-related prognostic model (IRPM) by lasso regression. Then, we used three hub genes to construct an IRPM for GBM and clarify the immunity, mutation, and methylation characteristics. ResultsSurvival analysis of patients undergoing anti-program cell death protein 1 (anti-PD-1) therapy showed that overall survival was superior in the low-risk group than in the high-risk group. The high-risk group had an association with epithelial-mesenchymal transition (EMT), high immune cell infiltration, immune activation, a low mutation number, and high methylation, while the low-risk group was adverse status. ConclusionsIn conclusion, IRPM is a promising tool to distinguish the prognosis of patients and molecular and immune characteristics in GBM, and the IRPM risk score can be used to predict patient sensitivity to checkpoint inhibitor blockade therapy. Thus, three immune-related signatures will guide us in improving treatment strategies and developing objective diagnostic tools.

学科与关键词

关键词
glioblastomaimmune genemutationmethylationPD-1
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Neurology
发表日期
2022-05-20
卷期
第 13 卷
页码
886913
DOI
10.3389/fneur.2022.886913
语言
ENGLISH
期刊等级
3区
成果收录
SCIE

作者

  • M

    Ma, Shuai (第一作者)

    zhejiang prov peoples hosp · 2 · zhengzhou univ

  • W

    Wang, Fang

    2 · harbin med univ

查看全部 8 位作者收起作者
  • W

    Wang, Nan

    zhejiang prov peoples hosp

  • J

    Jin, Jiaqi

    zhejiang prov peoples hosp

  • B

    Ba, Yixu

    zhejiang prov peoples hosp

  • J

    Ji, Hang

    zhejiang prov peoples hosp

  • D

    Du, Jianyang (通讯)

    shandong prov hosp

  • H

    Hu, Shaoshan (通讯)

    zhejiang prov peoples hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417